Many hematologic malignancies, including leukemia (AML/CML), myelodysplastic syndrome (MDS), and aplastic anemia, predominantly affect older adults. Allogeneic hematopoietic stem cell transplantation (AHSCT) offers a potential cure for intermediate- to high-risk disease. However, it is infrequently offered to patients older than 70 due to concerns about tolerability. AHSCT in elderly patients remains a challenge. Further studies are needed to refine patient selection criteria, identify key demog...